Asia Pacific Prenatal & Newborn Genetic Testing Market 2027 By Product, Technology, End User and Geography

Asia Pacific Prenatal & Newborn Genetic Testing Market to 2027 - Regional Analysis and Forecasts by Product (Diagnostic, and Screening), Disease Indication (Cystic Fibrosis, Sickle Cell Anemia, Down Syndrome, Phenylketonuria, Recurrent Pregnancy Loss, Antiphospholipid Syndrome (APL), and Other Diseases), Technology (Spectrophotometer, Polymerase Chain Reaction, Fluorescence In-situ Hybridization, Array Comparative Genomic Hybridization, and Others), End User (Hospitals & Clinics, Diagnostic Centers, and Other End User) and Geography

  • Report Code : TIPRE00006470
  • Category : Biotechnology
  • Status : Published
  • No. of Pages : 281
Buy Now

The Asia Pacific prenatal and newborn genetic testing market is expected to reach US$ 1,679.956 Mn in 2027 from US$ 630.914 in 2018. The market is estimated to grow with a CAGR of 11.6% from 2019-2027.

The key factors responsible for the growth of the Prenatal and Newborn Genetic testing market in Asia Pacific are rising burden of genetic diseases among infants, increasing fertility rates and developing healthcare scenario with rising awareness among populace regarding the benefits of prenatal testing. On the other hand, use of digital microfluidics in newborn testing is likely to be a prevalent trend in the future years. 

Lucrative Regional Markets

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.


Market Insights

Burden of Genetic Diseases in India

Several types of genetic diseases affect the fetuses in the womb. The way in which these genetic diseases are inherited helps to determine the risk that they pose on pregnancy as well as the risk of its recurrence. The risk of having genetic diseases in babies is high in cases where the parents have another child with a genetic disease, family history of a genetic disorder, or if either of a parent has a chromosomal abnormality. There is a significant prevalence of genetic diseases among infants. Moreover, these diseases are also responsible for infant mortality across the globe. Five most common genetic diseases in India affecting the new born are Beta-Thalassemia, Cystic Fibrosis, Sickle Cell Anemia, Spinal Muscular Atrophy and Hemophilia A. Sickle cell anemia is inherited blood disorder and is most common among African, Arabian and Indian population. The Indian pediatrics estimated that every year approximately 9,000-10,000 new born suffer from β-thalassemia. Furthermore, in 2011, India reported 14,718 cases with bleeding diseases and 11,586 patients with hemophilia A.

Furthermore, according to the previous study, “The burden of genetic disorders in India and a framework for community control” in 2002, estimated that approximately, 495,000 new-borns with congenital malformations, 21,400 with Down syndrome, 9,000 with beta-thalassemia, 5,200 with sickle cell disease are born each year. Due to presence of large population, high birth rate, consanguineous marriage in various Indian communities, there is a high incidence of genetic diseases in India. Thus, the high prevalence of genetic diseases among infants account for the increasing demands for prenatal and newborn genetic tests, thereby contributing to the growth of the market.

Development of Policy for Treatment of Rare Diseases

Genetic diseases are, in most cases, chronic, devastating and life threatening, which often requires extensive and specialized treatments. Moreover, these diseases results in some form of disability, which may get extremely severe sometimes. These genetic diseases place a huge psychological, physical, and socioeconomic burden on patients as well as their families. The most common rare diseases are hemophilia, thalassemia, sickle-cell anemia, auto-immune diseases, lysosomal storage disorders and others. Approximately 80% of rare diseases have identified to be of genetic origin and hence have an impact on children.
The government of India (GOI) had constituted committees with the aim of framing a ‘national policy on treatment of 17 rare diseases’. Likewise, the government of National Capital Territory (NCT) of Delhi also appointed an interdisciplinary committee for rare diseases. Following are the committees appointed for rare diseases:

  • Committee under Professor V.K. Paul, Head, Department of Paediatrics, AIIMS, New Delhi, for ‘Prioritisation of Therapy for Rare Genetic Disorders’
  • Sub-committee on rare diseases in India, under Prof. I.C. Verma, Director, Institute of Medical Genetics Genomics, Sir Ganga Ram Hospital – ‘Guidelines for Therapy and Management’

Thus, growing efforts by the Government is likely to boost the market and is expected to provide significant growth opportunities for the prenatal and new born genetic testing market during the forecast period.

Product Insights

The Asia Pacific prenatal and newborn genetic testing market, based on the product was segmented into screening and diagnostics. In 2018, the screening segment held a largest market share of the prenatal and newborn genetic testing market, by product. Moreover, the same segment is also expected to witness the highest CAGR over the coming years owing to the factors such as increasing number of pregnant females adopting prenatal screening, increased mandatory regulations for newborn screening tests and others. Moreover, screens are the first line tests that pregnant women and newborn undergoes that also adds up to the major share of the market and its dominance in the Asia Pacific market.

Prenatal and newborn genetic testing Market, by Product

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.



Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Asia Pacific Prenatal & Newborn Genetic Testing Market: Strategic Insights

asia-pacific-prenatal-and-newborn-genetic-testing-market
Market Size Value inUS$ 630.914 Million in 2018
Market Size Value byUS$ 1,679.956 Million by 2027
Growth rateCAGR of 11.6% from 2019-2027
Forecast Period2019-2027
Base Year2019
Analyst Image

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

Partnerships, Product up-gradation and product launches were observed as the most adopted strategy in Asia Pacific prenatal and newborn genetic testing industry. Few of the recent partnerships, product launch and up-gradations are listed below;

2019:

Illumina introduced VeriSeq NIPT Solution v2, a CE-IVD, next-generation sequencing (NGS)-based approach to noninvasive prenatal testing (NIPT). The automated comprehensive solution allows laboratories to screen for a broader range of chromosomal and sub-chromosomal conditions associated with birth defects and adverse pregnancy outcomes than the standard NIPT menu.

2017:

Natera, Inc. upgraded its Panorama non-invasive prenatal test (NIPT) to screen twin pregnancies for zygosity (identical or non-identical/fraternal) and chromosomal abnormalities.

2015:

SRL Diagnostics has introduced a breakthrough medical test to diagnose hypertensive disorders in pregnancy recently at its state of the art lab in Gurgaon. PLGF (Placental Growth Factor) is used for accurate diagnosis and prognosis of “pre-eclampsia”, a major cause of maternal, foetal, neonatal morbidity and mortality.

2017:

LifeCodexx AG, a non-invasive prenatal DNA testing company in Europe and LifeCell announced a partnership to bring PrenaTesT qNIPTTM testing for the first time to India. The qNIPT technology detects the presence of fetal trisomy 21 (Down syndrome) from maternal blood.

PRENATAL AND NEWBORN GENETIC TESTING – MARKET SEGMENTATION

By Test Type

  • Prenatal Genetic Testing
  • Newborn Genetic Testing

By Product

  • Screening
    • Maternal Serum Screening
    • Non-invasive Prenatal Testing
  • Diagnostic
    • Chronic Villus Sampling
    • Amniocentesis
    • Cytogenetic and Pharmacogenetic Testing

By Disease Indication

  • Cystic Fibrosis
  • Sickle Cell Anemia
  • Down Syndrome
  • Phenyketonuria
  • Recurrent Pregnancy Loss
  • Antiphospholipid Syndrome
  • Other Diseases

By Technology

  • Spectrophotometry
  • Polymerase Chain Reaction
  • Fluorescence in-situ Hybridization
  • Array Competitive Genomic Hybridization
  • Others

By End User

  • Hospitals & Clinics
  • Diagnostic Centres
  • Other End Users

By Geography

  • Asia Pacific

  • China
  • Japan
  • India
  • Indonesia
  • Singapore
  • Malaysia
  • Thailand
  • Pakistan
  • Bangladesh
  • Sri Lanka
  • Nepal

Company Profiles

  • LifeCell
  • Quest Diagnostics Incorporated
  • Medgenome
  • Eurofins Scientific
  • Metropolis India
  • SRL Diagnostics
  • Sandor Lifesciences Pvt Ltd
  • PerkinElmer, Inc.
  • Natera, Inc.
  • Laboratory Corporation of America Holdings (Sequenom)
  • Genes2Me LLP
  • Illumina, Inc.
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Product, Technology, End User and Geography

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

Australia, China, Japan, South Korea

The List of Companies - Asia Pacific Prenatal and Newborn Genetic Testing Market

  1. LifeCell
  2. Quest Diagnostics Incorporated
  3. Medgenome
  4. Eurofins Scientific
  5. Metropolis India
  6. SRL Diagnostics
  7. Sandor Lifesciences Pvt Ltd
  8. PerkinElmer, Inc.
  9. Natera, Inc.
  10. Laboratory Corporation of America Holdings (Sequenom)
  11. Genes2Me LLP
  12. Illumina, Inc.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Asia Pacific Prenatal & Newborn Genetic Testing Market